0001479290-18-000043.txt : 20180309 0001479290-18-000043.hdr.sgml : 20180309 20180309203654 ACCESSION NUMBER: 0001479290-18-000043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180307 FILED AS OF DATE: 20180309 DATE AS OF CHANGE: 20180309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Browne L Daniel CENTRAL INDEX KEY: 0001597583 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 18681701 MAIL ADDRESS: STREET 1: 7555 GATEWAY BOULEVARD CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 4 1 wf-form4_152064578880226.xml FORM 4 X0306 4 2018-03-07 0 0001479290 Revance Therapeutics, Inc. RVNC 0001597583 Browne L Daniel C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560 1 1 0 0 CEO and President Common Stock 2018-03-07 4 S 0 27283 31.43 D 131208 D Common Stock 409 I See footnote The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne. The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.85. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust. /s/ Gordon Ho, Attorney-in-Fact 2018-03-09